Date: 2014-03-28
Type of information:
phase:
Announcement: presentation of data at the EASL (European Association for the Study of the Liver) congress in London, in April 2014
Company: NeuroVive Pharmaceutical (Sweden)
Product: NVP018
Action
mechanism: NVP018 is an oral preparation of NeuroVive’s leading drug candidate in the company’s new portfolio of cyclophilin inhibitors. The recently acquired cyclophilin inhibitors are part of the family of molecules called Sangamides, and based on a new and unique chemical platform of what are known as polyketides. NVP018 is NeuroVive’s primary drug candidate in the company’s new portfolio of potent cyclophilin inhibitors. It has undergone extensive preclinical development and has been developed for treating hepatitis B/C. This product demonstrates potent efficacy against virus replication and has a positive safety and pharmacokinetic profile.
Disease: hepatitis B
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On March 28, 2014, NeuroVive has announced that its anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections. This new data will be presented at the EASL (European Association for the Study of the Liver) congress in London, in April 2014. The results indicate that NVP018 has a dual effect against the hepatitis B virus. Firstly, the data generated suggests that NVP018 directly inhibits several stages in viral propagation in liver cells, and secondly, NVP018 also operates indirectly by strengthening the immune response. The data also indicates that the risk of developing resistance, a significant clinical problem with current therapy alternatives for hepatitis B, is very low with NVP018. Finally, NVP018 also demonstrates activity in an animal model of chronic hepatitis B infection.
